Change from Baseline in cartilage thickness in the total femorotibial joint as evaluated by MRI at 2 years Baseline and 2 years [clinicaltrials_resource:bd7b21e380d7db8ca7db5e48d6db287f]
AS902330 will be administered at a dose of 100 microgram (mcg) in 4 cycles, wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Change from Baseline in cartilage thickness in the total femorotibial joint as evaluated by MRI at 2 years Baseline and 2 years [clinicaltrials_resource:bd7b21e380d7db8ca7db5e48d6db287f]
AS902330 will be administered at a dose of 100 microgram (mcg) in 4 cycles, wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
Bio2RDF identifier
bd7b21e380d7db8ca7db5e48d6db287f
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:bd7b21e380d7db8ca7db5e48d6db287f
measure [clinicaltrials_vocabulary:measure]
Change from Baseline in cartil ...... as evaluated by MRI at 2 years
time frame [clinicaltrials_vocabulary:time-frame]
Baseline and 2 years
description
AS902330 will be administered ...... ks, with follow-up to 2 years.
identifier
clinicaltrials_resource:bd7b21e380d7db8ca7db5e48d6db287f
title
Change from Baseline in cartil ...... t 2 years Baseline and 2 years
@en
type
label
Change from Baseline in cartil ...... b21e380d7db8ca7db5e48d6db287f]
@en